Stock 300255 HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Equities

300255

CNE1000016C2

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
11.2 CNY +0.09% Intraday chart for Hebei Changshan Biochemical Pharmaceutical Co., Ltd. -7.44% -13.91%
Apr. 28 Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 14 Yang Minghuan completed the acquisition of 5.8% stake in Hebei Changshan Biochemical Pharmaceutical Co., Ltd. from Gao Shuhua. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Yang Minghuan completed the acquisition of 5.8% stake in Hebei Changshan Biochemical Pharmaceutical Co., Ltd. from Gao Shuhua.
CI
Yang Minghuan entered into an agreement to acquire 5.8% stake in Hebei Changshan Biochemical Pharmaceutical Co., Ltd. from Gao Shuhua for CNY 490 million.
CI
Hebei Changshan Biomedical Pharma's Controlling Shareholder to Sell 5.8% Company Stake
CI
Changshan Biochemical Pharmaceutical, Unit Get Nod to Trial Tumor Drug
MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Changshan Biochemical Pharmaceutical Gets Nod to Register Deep Vein Thrombosis Drug in Lebanon
MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(XSEC:300255) added to S&P Global BMI Index
CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Changshan Biochemical Pharma Registers Enoxaparin Sodium Injection in Nicaragua
MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022, Payable on June 27, 2023
CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022
CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Changshan Biochemical Pharma’s Deep Vein Thrombosis Drug Shortlisted For China’s Drug Procurement Program
MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(XSEC:300255) dropped from S&P Global BMI Index
CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Changshan Biochemical Wins Nod to Register Vein Thrombosis Drug in Turkmenistan
MT
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(XSEC:300255) added to S&P Global BMI Index
CI
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300255 Stock
  4. News Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Over 1,000,000 investors have joined us.
Thank you!
Days
Hours
Minutes
Seconds
Subscribe now
Over 1,000,000 investors have joined us.
Thank you!
Days
Hours
Minutes
Seconds
Subscribe now